Hepatitis C Partnership – Terms of Reference
1. To establish a national collaborative network of stakeholders working in the area of Hepatitis C across the community/voluntary/statutory sectors with service user involvement at its centre.
2. To provide a centralised information hub for all voluntary/community groups working with people with Hepatitis C and explore options around annual information meetings/conferences, social media information sharing/networking.
3. To enhance and strengthen the support and information sharing network through the community/voluntary sector by working collaboratively with the service providers and groups such as ICORN, the HSE National Hepatitis C Strategy Implementation Group and the Consultative Council on Hepatitis C.
4. To undertake and participate in public awareness campaigns which promote testing, treatment and general health promotion in relation to Hepatitis C, together with the above groups.
5. To share the many experiences of the already established Hepatitis C networks in the community and provide a platform for service user experience to be heard and communicated onto the service providers.
6. To advocate for the continued rollout of the HSE National Hepatitis C Strategy through national collaboration.
Hepatitis and PWID/harm reduction
11:35 – 11:40
Chair: WHO – Intro and set the scene.
11:40 – 11:55
Co-chair: EMCDDA – Monitoring viral hepatitis elimination among PWID in Europe.
11:55 – 12:00
ID 29: Ema Pos (not yet registered)
Title: If the mountain won’t come to Mohammed: lessons from a decentralized Infectious Disease consultation.
12:05 – 12:10
ID 152: Brian Conway (Registered in person)
Title: Community Pop-up Clinic: Cascade of Care and HCV Treatment of Vancouver’s inner-city PWID Populations.
12:10 – 12:15
ID 212: Jasmine West (not yet registered)
Title: From lived experience to lived expertise: a syndemic approach.
12:15 – 12:20
ID: 299 Mercy Nyakowa (Registered in person)
Title: HCV and HBV prevalence and associated risk factors among people who inject drugs (PWIDs) in Kenya
12:20 – 12:25
ID: 133 Nalinikanta Rajkumar (Registered in person)
Title: Rapid regimen of HBV vaccination: Does it work for high risk groups?
12:25 – 12:30
Q&A and closing remarks
tHIS
IS
BEN’S
BIG
TEST
effective case finding strategies
Supported by Vir Biotechnology, Inc
During this session you will hear from hepatitis Delta expert, Dr. Maria Buti, and a patient who has lived with hepatitis Delta in a panel discussion moderated by Dr. Carey Hwang, Chief Medical Officer (interim) of Vir Biotechnology. This panel will inform perspectives on patient needs, opportunities for enhanced screening, and strengthening linkages to care.
Session Agenda
14:40 – 14:45
Panel overview and introductions facilitated by Dr Carey Hwang (Vir Biotechnology)
14:45 – 15:05
Panel discussion: Dr Maria Buti (University Hospital Vall d’Hebron, Spain), Milanka Barbosa, Dr Carey Hwang (Chief Medical Officer interim), Vir Biotechnology
15:05 – 15:10
Final remarks and close